Literature DB >> 27645819

Therapeutic Drug Monitoring of Mycophenolic Acid.

A Dasgupta1.   

Abstract

Mycophenolic acid (MPA) is an immunosuppressant requiring therapeutic drug monitoring. Although immunoassays are commercially available, there is significant positive bias using this approach when compared to high-performance liquid chromatography or LC combined with mass spectrometry (LC/MS) or tandem mass spectrometry (LC/MS/MS). Positive bias is due to variable cross-reactivity of MPA acyl glucuronide with antibodies traditionally used in immunoassay formats. As can be expected, the magnitude of bias varies considerably. MPA strongly binds albumin and, as a result, disproportionate increases in free MPA occur in patients with uremia, hypoalbuminemia, and hepatic dysfunction. As such, monitoring free MPA poses additional challenges. Because MPA inhibits inosine monophosphate dehydrogenase, monitoring this enzyme may provide an alternative approach.
© 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Free fraction; Immunoassay; Liquid chromatography tandem mass spectrometry; MPA; TDM

Mesh:

Substances:

Year:  2016        PMID: 27645819     DOI: 10.1016/bs.acc.2016.04.001

Source DB:  PubMed          Journal:  Adv Clin Chem        ISSN: 0065-2423            Impact factor:   5.394


  6 in total

1.  Investigation of the Association Between Total and Free Plasma and Saliva Mycophenolic Acid Concentrations Following Administration of Enteric-Coated Mycophenolate Sodium in Adult Kidney Transplant Recipients.

Authors:  Emily Brooks; Susan E Tett; Nicole M Isbel; Brett McWhinney; Christine E Staatz
Journal:  Clin Drug Investig       Date:  2019-12       Impact factor: 2.859

2.  The Impact of Genetic Polymorphisms on the Pharmacokinetics and Pharmacodynamics of Mycophenolic Acid: Systematic Review and Meta-analysis.

Authors:  Mingkwan Na Takuathung; Wannachai Sakuludomkan; Nut Koonrungsesomboon
Journal:  Clin Pharmacokinet       Date:  2021-06-09       Impact factor: 6.447

3.  Drug Repurposing for Therapeutic Discovery against Human Metapneumovirus Infection.

Authors:  Annelies Van Den Bergh; Patrice Guillon; Mark von Itzstein; Benjamin Bailly; Larissa Dirr
Journal:  Antimicrob Agents Chemother       Date:  2022-09-12       Impact factor: 5.938

Review 4.  Optimizing Mycophenolic Acid Exposure in Kidney Transplant Recipients: Time for Target Concentration Intervention.

Authors:  David K Metz; Nick Holford; Joshua Y Kausman; Amanda Walker; Noel Cranswick; Christine E Staatz; Katherine A Barraclough; Francesco Ierino
Journal:  Transplantation       Date:  2019-10       Impact factor: 4.939

5.  Validated Simple HPLC-UV Method for Mycophenolic Acid (MPA) Monitoring in Human Plasma. Internal Standardization: Is It Necessary?

Authors:  Paweł K Kunicki; Aleksandra Wróbel
Journal:  Molecules       Date:  2021-11-29       Impact factor: 4.411

6.  A Tissue-Tended Mycophenolate-Modified Nanoparticle Alleviates Systemic Lupus Erythematosus in MRL/Lpr Mouse Model Mainly by Promoting Local M2-Like Macrophagocytes Polarization.

Authors:  Biling Jiang; Yamin Zhang; Yuce Li; Yu Chen; Shanshan Sha; Liang Zhao; Danqi Li; Jingjing Wen; Jiajia Lan; Yuchen Lou; Hua Su; Chun Zhang; Jintao Zhu; Juan Tao
Journal:  Int J Nanomedicine       Date:  2022-07-28
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.